Clinical Trial

IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 5, 2024 (before its estimated March 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a single-arm, single-center, open-label clinical study aimed at evaluating the safety and efficacy of IX001 TCR-T (T cell receptor-engineered T-Cell) injection in patients with advanced pancreatic cancer and colorectal cancer induced by KRAS (Kirsten Rat Sarcoma Viral Oncogene) mutations. A total of 6-18 evaluable patients are planned to be enrolled. The study will include 4 dose groups, using a '3+3' dose escalation design.
Trial Details
NCT Number NCT06487377
Lead Sponsor Shanghai Pudong Hospital
Collaborators: ImmuXell Biotech Ltd.
Conditions Pancreatic Cancer, Colorectal Cancer
Enrollment 12 participants
Start Date 2024-07
Primary Completion 2025-03 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-07-05